Video

Dr. Stacy Loeb on Considerations for Screening in Prostate Cancer

Author(s):

, assistant professor of urology and population health at New York University (NYU) Langone Medical Center, discusses screening determinations for prostate cancer.

Stacy Loeb, MD, assistant professor of urology and population health at New York University (NYU) Langone Medical Center, discusses screening determinations for prostate cancer.

It is important that patients receive a baseline measurement of PSA in their 40s. What that level is in a younger man actually gives oncologists an idea as to what their life risk of having life-threatening prostate cancer is.

To reduce the downstream harm from screening, oncologists need to be selective about treatment, says Loeb.

Active surveillance is really on the rise in both Europe and in the United States. Saving aggressive treatment for aggressive cancer, and encouraging active surveillance for low-risk disease can reduce the risks of overtreatment.

Related Videos
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS
Rona Yaeger, MD
 PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Robert
Charles B. Nguyen, MD
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC